A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Journal of Clinical Medicine · 06.07.2023 · 12 (13) · 4527
DOI: 10.3390/jcm12134527 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.07.2023. Verfasst von Peter C Taylor und 9 weiteren Autor:innen. Beteiligte Einrichtung: Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheumatoid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Currently, baricitinib is approved for treating RA in more than 75 countries. In several pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of baricitinib treatment was well tolerated and provided rapid and sustained efficacy, which was confirmed in real-world settings. Safety signals for another JAK inhibitor, tofacitinib, have emerged, as observed in the post-marketing Phase IIIb/IV trial Oral Rheumatoid Arthritis Trial (ORAL) Surveillance; safety signals were subsequently highlighted in a retrospective study of baricitinib and consequently new recommendations and warnings and precautions for all JAK inhibitors have been issued. Ongoing studies to further characterise and clarify the benefit:risk of JAK inhibitors include registries and controlled trials. This capstone review summarises clinical and real-world data outlining the benefit:risk profile of baricitinib, confirming that the improved disease activity and physical function of patients with RA treated with this JAK inhibitor observed in clinical trials is translated into effectiveness in clinical practice, with a low rate of discontinuations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
- Eli Lilly and Company, Indianapolis, IN 46285, USA.
- Internal Medicine II, Rheumatology, SCHLOSSPARK-KLINIK, University Medicine Berlin, 14059 Berlin, Germany.
- Department of Rheumatology, Helios Clinic Vogelsang-Gommern, Cooperation Partner of the Otto-von-Guericke University Magdeburg, 39245 Magdeburg, Germany.
- Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4YS, UK.
- Service de Rhumatologie, Hôpital Lariboisière, 75010 Paris, France.
ORCID-Profile: Peter C Taylor, Axel Finckh, Yoshiya Tanaka
Förderung
- Eli Lilly and Company
Zitieren
APA
Taylor, P. C., Laedermann, C., Alten, R., Feist, E., Choy, E., Haladyj, E., De La Torre, I., Richette, P., Finckh, A., & Tanaka, Y. (2023). A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. Journal of Clinical Medicine, 12(13), 4527. https://doi.org/10.3390/jcm12134527
Vancouver
Taylor PC, Laedermann C, Alten R, Feist E, Choy E, Haladyj E, et al. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. Journal of Clinical Medicine. 2023;12(13):4527. doi:10.3390/jcm12134527
BibTeX
@article{Taylor2023,
author = {Taylor, Peter C and Laedermann, Cedric and Alten, Rieke and Feist, Eugen and Choy, Ernest and Haladyj, Ewa and De La Torre, Inmaculada and Richette, Pascal and Finckh, Axel and Tanaka, Yoshiya},
title = {A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {13},
pages = {4527},
doi = {10.3390/jcm12134527}
}
EUVIMED